Results 111 to 120 of about 3,939 (188)

A mathematical modeling technique to understand the role of decoy receptors in ligand-receptor interaction. [PDF]

Sci Rep, 2023
Dey S, Ghosh A, Banerjee M.
europepmc   +1 more source

TRAF2 and RIPK1 redundantly mediate classical NFκB signaling by TNFR1 and CD95-type death receptors. [PDF]

Cell Death Dis
Wagner J, Vredevoogd D, Yu X, Lu D, Peeper DS, Hermanns HM, Wang J, Wajant H, Siegmund D.   +8 more
europepmc   +1 more source

Pharmacological targeting of caspase-8/c-FLIP_L heterodimer enhances complex II assembly and elimination of pancreatic cancer cells. [PDF]

Commun Biol
König C, Ivanisenko NV, Ivanisenko VA, Kulms D, Lavrik IN.   +4 more
europepmc   +1 more source

Protocol for measuring the caspase-8 activity at the DED filaments in adherent cells. [PDF]

STAR Protoc
König C, Lavrik IN.
europepmc   +1 more source

Targeting caspase-8/c-FLIP_L heterodimer in complex II promotes DL-mediated cell death. [PDF]

Front Cell Dev Biol
Hillert-Richter LK, König C, Ivanisenko NV, Reinhold D, Lavrik IN.   +4 more
europepmc   +1 more source

Fas Ligand (CD95L) and Cancer Gene Therapy [PDF]

Nature Biotechnology, 1999
openaire   +1 more source

CD95 Ligand (CD95L) in Normal Human Lymphoid Tissues [PDF]

The American Journal of Pathology, 1999
Jörn Sträter, Sara M. Mariani, Henning Walczak, Frank G. Rücker, Frank Leithäuser, Peter H. Krammer, Peter Möller   +6 more
openaire   +1 more source

Cervical Cancer Cells Use the CD95 and IL-2 Pathways to Promote Their Proliferation and Survival. [PDF]

Biomolecules
Gutiérrez-Hoya A, Ortiz-Garrido I, Salazar-Valencia I, Romero-Hernández C, Valle-Mendiola A, Weiss-Steider B, Soto-Cruz I.   +6 more
europepmc   +1 more source

Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells. [PDF]

Cancers (Basel), 2022
Tan GMY, Poudel A, Ali Hosseini Rad SM, McLellan AD.   +3 more
europepmc   +1 more source

Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial. [PDF]

EClinicalMedicine
Ruiz Seco MP, Paño Pardo JR, Schoergenhofer C, Dings C, Lehr T, Herth F, Krendyukov A, Straub C, Kappler M, Jilma B, Fricke H, Pardo J, de Miguel D, Thiemann M, Bergmann M, Walczak H, Hoeger T.   +16 more
europepmc   +1 more source